Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRG-002
- Development stage
- Phase 1
- Lead developer
- Celregen
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intraportal, Implantation
01
Overview
CRG-002 is an investigational cell therapy product consisting of allogeneic induced pluripotent stem cell (iPSC)-derived pancreatic islet cells. Developed by Celregen Therapeutics, a Shanghai-based regenerative medicine company incubated by Fosun Health Capital, CRG-002 is designed to restore glycemic control in patients with type 1 diabetes mellitus (T1DM) or pancreatogenic diabetes mellitus. The therapy specifically targets patients experiencing hypoglycemia unawareness or severe hypoglycemic events by replacing or supplementing the function of endogenous pancreatic islet cells. CRG-002 is administered via intraportal infusion or implantation beneath the anterior rectus sheath and is currently undergoing evaluation in early-phase clinical trials to assess its safety and preliminary efficacy.
- Other names
- allogeneic iPSC-derived pancreatic islet cells
Beyond the preview
Go deeper on CRG-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRG-002.